TG Therapeutics I…
USUSDTG Therapeutics Inc (US:TGTX) — Biotechnology: Pharmaceutical Preparations. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 2. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.
À propos de l'entreprise
- Site Web
- tgtherapeutics.com
- Secteur
- Health Care · Biotechnology: Pharmaceutical Preparations
- Siège Social
- New York City, United States
- PDG
- Michael S. Weiss
- Employés
- 399
- Actions en Circulation
- 153.07 M au 2026-08-03
- Flottant
- 135.24 M
- Capitalisation Boursière
- 8.31 Md USD
- Initiés
- 7.47%
- Investisseurs Institutionnels
- 74.41%
- Secteur d'Activité (SIC)
- Pharmaceutical Preparations
- ISIN
- US88322Q1085
- LEI
- 529900X21UKABN9NJ529
- FCF
- 17.4 M USD
- Dette
- 745 M USD15 ans de FCF
- Résultats et FCF — pour les 12 mois à 30.06.2026 (dernier rapport de l'entreprise).
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Principaux Actionnaires
| Détenteur | Participation | Actions | Date du Rapport |
|---|---|---|---|
| Blackrock Inc. | 14.41% | 22.05 M | 2026-06-30 |
| WEISS MICHAEL S (Chief E… | ≈6.39% | 9.78 M | 2026-01-08 |
| iShares Trust-iShares Co… | 5.25% | 8.03 M | 2026-08-31 |
| Vanguard Portfolio Manag… | 5.2% | 7.96 M | 2026-06-30 |
| State Street Corporation | 5.09% | 7.79 M | 2026-06-30 |
| Vanguard Capital Managem… | 4.02% | 6.15 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.86% | 4.38 M | 2026-06-30 |
| iShares Trust-iShares Ru… | 2.42% | 3.71 M | 2026-08-31 |
| Geode Capital Management… | 2.38% | 3.64 M | 2026-06-30 |
| Shaw D.E. & Co., Inc. | 2.22% | 3.4 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.06% | 3.16 M | 2026-06-30 |
| Soleus Capital Managemen… | 1.91% | 2.93 M | 2026-06-30 |
| Price (T.Rowe) Associate… | 1.81% | 2.77 M | 2026-06-30 |
| ClearBridge Investments,… | 1.73% | 2.65 M | 2026-06-30 |
| Congress Asset Managemen… | 1.7% | 2.6 M | 2026-06-30 |
| SPDR SERIES TRUST-State… | 1.47% | 2.25 M | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 1.19% | 1.82 M | 2026-06-30 |
| Fidelity Salem Street Tr… | 1.04% | 1.59 M | 2026-07-31 |
| First TRT Exch-Trd Fd.-F… | 1.04% | 1.59 M | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 0.99% | 1.51 M | 2026-06-30 |
| iShares Trust-iShares Ru… | 0.89% | 1.36 M | 2026-08-31 |
| POWER SEAN A (Chief Fina… | ≈0.52% | 798 111 | 2026-01-08 |
| HOBERMAN KENNETH (Direct… | ≈0.18% | 279 653 | 2025-06-12 |
| ECHELARD YANN (Director) | ≈0.15% | 223 816 | 2025-11-24 |
| HUME DANIEL (Director) | ≈0.13% | 192 748 | 2025-06-12 |
| CHARNEY LAURENCE NEIL (D… | ≈0.11% | 168 640 | 2026-09-10 |
| LONIAL SAGAR (Director) | ≈0.06% | 94 061 | 2025-09-11 |
